125 completed, 56 recruiting, 27 unknown, 23 active not recruiting. 91 Phase 2, 47 Not applicable, 33 Phase 3, 25 Phase 1, 11 Phase 4.
Follow Hidradenitis: new trials by email Literature Review of Hidradenitis trials Research Report on Hidradenitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Early Secukinumab Treatment in Moderate to Severe Hidradenitis Suppurativa Patients Hidradenitis Suppurativa | Not yet recruiting | Novartis Pharmaceuticals | 186 | 2026-11-13 | 2026-10-20 | |
| Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity Olatorepatide, Placebo - Hidradenitis Suppurativa | Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 300 | 2026-10-30 | 2026-09-21 |
| A Real-world Study of Patients With Hidradenitis Suppurativa and High Cardiovascular Risk or Established Coronary Plaque Treated With Secukinumab Hidradenitis Suppurativa | Not yet recruiting | Novartis Pharmaceuticals | 34 | 2026-10-30 | 2026-09-21 | |
| A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HS LOU064, Placebo - Hidradenitis Suppurativa | Phase 1 | Recruiting | Novartis Pharmaceuticals | 30 | 2026-10-15 | 2026-10-16 |
| A Study to Investigate Efficacy and Safety of Duvakitug in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Duvakitug, Placebo - Hidradenitis | Phase 2 | Not yet recruiting | Sanofi | 156 | 2026-10-13 | 2026-10-14 |
| Skin-in-Sight: a Longitudinal Cohort Infrastructure for Standardized Remote Monitoring and the Evaluation of Digital Care Innovations in Chronic Skin Diseases Psoriasis, Eczema/Atopic Dermatitis | Not yet recruiting | Medisch Spectrum Twente | 1000 | 2026-10-01 | 2026-09-04 | |
| Botulinum Toxin Blockade of Neuronal Signals to Immune Cells as a Novel Treatment for Hidradenitis Suppurativa Botulinum Toxin A (Allergan, Inc, Irvine CA), Placebo - Hidradenitis Suppurativa (HS) | Phase 2 | Not yet recruiting | University of Massachusetts, Worcester | 40 | 2026-10-01 | 2026-09-10 |
| Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa Soquelitinib - Hidradenitis Suppurativa (HS) | Phase 1 | Recruiting | Corvus Pharmaceuticals, Inc. | 25 | 2026-09-17 | 2026-10-15 |
| Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa Roflumilast 0.3% topical foam - Hidradenitis Suppurativa (HS) | Phase 2 | Recruiting | Harrison Dermatology | 10 | 2026-09-10 | 2026-10-13 |
| The Safety and Efficacy of Roflumilast Foam in HS Roflumilast 0.3% topical foam - Hidradenitis Suppurativa (HS) | Phase 2 | Recruiting | Beth Israel Deaconess Medical Center | 20 | 2026-09-01 | 2026-07-09 |
| Mediterranean Dietary Intervention for HS Mediterranean Diet Counseling, Mediterranean Food Support - Hidradenitis Suppurativa | Not applicable | Not yet recruiting | University of North Carolina, Chapel Hill | 30 | 2026-09-01 | 2026-09-02 |
| An Observational Study of Patients With Dermatologic Disease Vitiligo, Atopic Dermatitis | Not yet recruiting | Target PharmaSolutions, Inc. | 2000000 | 2026-09-01 | 2026-09-10 | |
| A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial) SPY072, Placebo, bimekizumab - Hidradenitis Suppurativa (HS) | Phase 2 | Recruiting | Spyre Therapeutics, Inc. | 150 | 2026-09-01 | 2026-10-19 |
| Urinary Bladder Matrix (UBM) Registry Urinary Bladder Matrix (UBM) Products - Tissue Repair, Soft Tissue Reconstruction | Not yet recruiting | Integra LifeSciences Corporation | 300 | 2026-08-31 | 2026-09-04 | |
| ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa ORKA-002, Placebo - Hidradenitis Suppurativa (HS) | Phase 2 | Recruiting | Oruka Therapeutics, Inc. | 200 | 2026-08-21 | 2026-09-24 |
| An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS Remibrutinib - Hidradenitis Suppurativa | Phase 3 | Recruiting | Novartis Pharmaceuticals | 710 | 2026-07-10 | 2026-10-13 |
| Nd:YAG vs Alexandrite Laser Treatment in Hidradenitis Suppurativa Nd:YAG Laser, Alexandrite Laser - Hidradenitis Suppurativa (HS) | Not applicable | Not yet recruiting | Geisinger Clinic | 21 | 2026-07-01 | 2026-04-28 |
| A 24-Week Real-World Study of Upadacitinib in Moderate-to-Severe Hidradenitis Suppurativa Upadacitinib - Hidradenitis Suppurativa (Acne Inversa) | Phase 2 | Active not recruiting | Peking Union Medical College | 50 | 2026-07-01 | 2026-07-27 |
| Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa Secukinumab - Hidradenitis Suppurativa (HS) | Phase 4 | Recruiting | Novartis Pharmaceuticals | 36 | 2026-06-01 | 2026-09-09 |
| FEcal tranSplantation in HidradeniTIs suppuratiVA : a piLot Study Fecal microbiota transplantation (FMT) - Hidradenitis Suppurativa (HS), Fecal Microbiota Transplantation (FMT) | Phase 1 | Not yet recruiting | University Hospital, Clermont-Ferrand | 24 | 2026-06-01 | 2026-06-25 |
Showing 20 of 286. Sign in to see all of them.
Hidradenitis Suppurativa (280) · Psoriasis (23) · Dermatitis, Atopic (21) · Skin Diseases (19) · Alopecia Areata (11) · Arthritis, Rheumatoid (9) · Vitiligo (9) · Abscess (8) · Acne Vulgaris (8) · Arthritis, Psoriatic (8) · Colitis, Ulcerative (8) · Crohn Disease (8) · Sweat Gland Diseases (7) · Skin Diseases, Bacterial (6)
Skin and Connective Tissue Diseases (285) · Bacterial Infections (280) · Bacterial Infections and Mycoses (280) · Skin Diseases, Infectious (280) · Infections (279) · Sweat Gland Diseases (279) · Suppuration (275) · Skin Diseases, Bacterial (274) · Skin Diseases (267) · Immune System Diseases (34) · Pathological Conditions, Signs and Symptoms (32) · Pathologic Processes (29) · Skin Diseases, Papulosquamous (29) · Hypersensitivity (25)
Adalimumab (16) · secukinumab (14) · bimekizumab (7) · remibrutinib (5) · sonelokimab (5) · Sodium Chloride (4) · brodalumab (4) · upadacitinib (4) · Blood Specimen Collection (3) · Botulinum Toxins, Type A (3) · Lasers (3) · Lasers, Solid-State (3) · Roflumilast (3) · apremilast (3) · guselkumab (3)
Novartis Pharmaceuticals (21) · AbbVie (15) · Incyte Corporation (12) · Henry Ford Health System (7) · Sanofi (7) · UCB Biopharma SRL (6) · University of Miami (6) · Montefiore Medical Center (5) · MoonLake Immunotherapeutics AG (5) · Boehringer Ingelheim (4) · Florida Academic Dermatology Centers (4) · Janssen Research & Development, LLC (4) · Peking Union Medical College (4) · Rockefeller University (4) · University of North Carolina, Chapel Hill (4)
United States (160) · Canada (66) · Germany (66) · France (53) · Spain (52) · Poland (45) · Netherlands (40) · Australia (34) · Greece (31) · Italy (29) · Belgium (25) · Bulgaria (25) · Czechia (24) · Denmark (23) · China (22)
Hadar Lev-Tov, MD (5) · Christopher J Sayed, MD (3) · John W Frew, MD (3) · Steven R Cohen, MD, MPH (3) · Antoni Font Guiteras, PhD (2) · Antonio Martorell, PhD (2) · Baoxi Wang, Master (2)
PMID 27518661, PMID 29380251, PMID 31604104, PMID 36746171, PMID 41248770, PMID 42525209, PMID 22236226, PMID 23247938, PMID 32460374, PMID 34252397, PMID 34978076, PMID 38795716, PMID 39101698, PMID 39141589, PMID 39425517, PMID 40153232, PMID 40172122, PMID 40372667, PMID 40652434, PMID 40839197, PMID 41107641, PMID 41689425, PMID 42247110, PMID 42493571, PMID 12140476, PMID 14632813, PMID 16918566, PMID 17587838, PMID 19036028, PMID 19185954, PMID 19293006, PMID 19438670, PMID 20039918, PMID 20115947, PMID 20166154, PMID 20227579, PMID 20479297, PMID 23460557, PMID 23904820, PMID 24807602, PMID 25396122, PMID 25640693, PMID 26119625, PMID 26470622, PMID 26579854, PMID 27136622, PMID 27692735, PMID 28027202, PMID 29439003, PMID 30087573
2025 (9), 2023 (8), 2018 (5), 2019 (3), 2004 (1), 2008 (1), 2015 (1), 2017 (1), K08AR080844 (1), KL2RR031974 (1), R01NR013888 (1), R33AR077495 (1), R61AR087105 (1), UL1RR031975 (1)